Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399679 · ClinicalTrials.gov registry record · Phase 2
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium
A Phase 2 study of Anticholinergic Toxicity, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT06399679 is a Phase 2 study of Anticholinergic Toxicity that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 42 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06399679, a Phase 2 study of Anticholinergic Toxicity, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rivastigmine
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06399679
The ClinicalTrials.gov registry entry for NCT06399679 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anticholinergic Toxicity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06399679 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06399679 about?
NCT06399679 is a clinical study titled "Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium". Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after...
What is the current status of trial NCT06399679?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2024-11-04. Estimated completion is 2026-11.
What conditions does trial NCT06399679 study?
This clinical trial studies the following conditions: Anticholinergic Toxicity.
What interventions are being tested in trial NCT06399679?
The interventions under investigation include: Placebo (DRUG), Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT06399679?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399679 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.